The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype

被引:25
作者
Damiani, Daniela
Tiribelli, Mario
Raspadori, Donatella
Michelutti, Angela
Gozzetti, Alessandro
Calistri, Elisabetta
Candoni, Anna
Chiarvesio, Alexsia
Lenoci, Mariapia
Russo, Domenico
Fanin, Renato
机构
[1] Univ Udine, Chair Hematol, I-33100 Udine, Italy
[2] Univ Udine, Div Hematol & Bone Marrow Transplantat, I-33100 Udine, Italy
[3] Univ Siena, Chair Hematol, I-53100 Siena, Italy
[4] Univ Siena, Div Hematol, I-53100 Siena, Italy
[5] Univ Brescia, Chair Hematol, Brescia, Italy
[6] Univ Brescia, Unit Blood Dis & Cell Therapy, Brescia, Italy
关键词
acute myeloid leukaemia; normal karyotype; multidrug resistance; prognosis;
D O I
10.1002/hon.806
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cytogenetic abnormalities are among the most important factors affecting the outcome of patients with acute myeloid leukaemia (AML), but approximately 40-50% of AML cases display a normal karyotype at diagnosis. Multidrug resistance (MDR) proteins overexpression is associated with worse prognosis in acute leukaemias, but its role in normal karyotype AML is less defined. We analysed the expression of P-glycoprotein (PGP), MDR-related protein (MRP) and lung resistance protein (LRP) in 135 adult patients with normal karyotype AML and its correlation with other biological features of the disease, to evaluate the impact of MDR proteins on response to therapy and on survival. Increased PGP expression was associated with lower rate of complete remission (CR; p = 0.006), similarly to advanced age. Cases overexpressing PGP displayed also a shorter event-free survival (EFS; 4 vs. 10 months,p = 0.035) and the increased expression of at least one MDR protein was associated with a reduced overall survival (OS; p = 0.038). Also age was predictive of worse prognosis. Our data confirm the prognostic role of MDR proteins, in particular of PGP, also in AML patients with normal karyotype at diagnosis. This finding could be used to stratify patients with different prognosis and to design risk-adapted therapeutic strategies. Copyright (c) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:38 / 43
页数:6
相关论文
共 26 条
  • [1] Baldus CD, 2004, BLOOD, V104, p133B
  • [2] PROPOSALS FOR CLASSIFICATION OF ACUTE LEUKEMIAS
    BENNETT, JM
    CATOVSKY, D
    DANIEL, MT
    FLANDRIN, G
    GALTON, DAG
    GRALNICK, HR
    SULTAN, C
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1976, 33 (04) : 451 - &
  • [3] FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype
    Beran, M
    Luthra, R
    Kantarjian, H
    Estey, E
    [J]. LEUKEMIA RESEARCH, 2004, 28 (06) : 547 - 550
  • [4] Risk assessment in patients with acute myeloid leukemia and a normal karyotype
    Bienz, M
    Ludwig, M
    Mueller, BU
    Leibundgut, EO
    Ratschiller, D
    Solenthaler, M
    Fey, MF
    Pabst, T
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (04) : 1416 - 1424
  • [5] Bloomfield CD, 1997, CANCER-AM CANCER SOC, V80, P2191
  • [6] Bloomfield CD, 1998, CANCER RES, V58, P4173
  • [7] DelPoeta G, 1996, BLOOD, V87, P1997
  • [8] Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
    Falini, B
    Mecucci, C
    Tiacci, E
    Alcalay, M
    Rosati, R
    Pasqualucci, L
    La Starza, R
    Diverio, D
    Colombo, E
    Santucci, A
    Bigerna, B
    Pacini, R
    Pucciarini, A
    Liso, A
    Vignetti, M
    Fazi, P
    Meani, N
    Pettirossi, V
    Saglio, G
    Mandelli, F
    Lo-Coco, F
    Pelicci, P
    Martelli, MF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03) : 254 - 266
  • [9] Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype:: A cancer and leukemia group B study
    Farag, SS
    Ruppert, AS
    Mrózek, K
    Mayer, RJ
    Stone, RM
    Carroll, AJ
    Powell, BL
    Moore, JO
    Pettenati, MJ
    Koduru, PRK
    Stamberg, J
    Baer, MR
    Block, AW
    Vardiman, JW
    Kolitz, JE
    Schiffer, CA
    Larson, RA
    Bloomfield, CD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (03) : 482 - 493
  • [10] Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm
    Fröhling, S
    Schlenk, RF
    Breitruck, J
    Benner, A
    Kreitmeier, S
    Tobis, K
    Döhner, H
    Döhner, K
    [J]. BLOOD, 2002, 100 (13) : 4372 - 4380